Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 2670.

https://doi.org/10.1182/blood-2019-131949

Published: 2019

Journal Articles

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3936.

https://doi.org/10.1182/blood-2019-131759

Published: 2019

Journal Articles

Probing Distinct Oncogene Addiction By Novel BCL-2 Inhibitors

Jing Deng, PhD, Yan Yin, MS, Tingting Mao, MS, Guoqin Zhai, MS, Dongmei Yang, MS, Douglas Fang, MD PhD, Shaomeng Wang, PhD, Yifan Zhai, MD PhD, Dajun Yang, MD PhD

Blood (2018) 132 (Supplement 1): 2616.

https://doi.org/10.1182/blood-2018-99-119816

Published: 2018

Journal Articles

Functional Analyses of BTK Mutations in Follicular Lymphoma

Nan Hu, PhD, Fangyang Wang, Denzil Bernard, Shaomeng Wang, Mark Kaminski, Sumana Devata, MD, Tycel J. Phillips, MD, Sami N. Malek, MD

Blood (2017) 130 (Supplement 1): 647.

https://doi.org/10.1182/blood.V130.Suppl_1.647.647

Published: 2017

Journal Articles

Functional Analyses of V-Atpase Mutations in Follicular Lymphoma

Fangyang Wang, Damian Gatica, Zhang Xiao Ying, Luke F. Peterson, Denzil Bernard, Kamlai Saiya-Cork, Shaomeng Wang, Alfred Chang, Mark S Kaminski, MD, Tycel Phillips, MD, Daniel Klionsky, Sami N. Malek

Blood (2016) 128 (22): 1762.

https://doi.org/10.1182/blood.V128.22.1762.1762

Published: 2016

Journal Articles

Analysis of 54 Follicular Lymphomas By Whole Exome Sequencing Identifies Multiple Novel Recurrently Mutated Pathways

Sami N. Malek, Denzil Bernard, Zhang Xiao Ying, Luke F. Peterson, Nisar A. Amin, Shaomeng Wang, Kamlai Saiya-Cork, Mark S. Kaminski, Alfred Chang

Blood (2015) 126 (23): 112.

https://doi.org/10.1182/blood.V126.23.112.112

Published: 2015

Journal Articles

BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice

Yaping Sun, Ying Wang, Tomomi Toubai, Katherine Oravecz-Wilson, Chen Liu, Nathan Mathewson, Julia Wu, Corinne Rossi, Emily Cummings, Depei Wu, Shaomeng Wang, Pavan Reddy

Blood (2015) 125 (17): 2724–2728.

https://doi.org/10.1182/blood-2014-08-598037

Published: 2015

Journal Articles

Activating STAT6 mutations in follicular lymphoma

Mehmet Yildiz, Hongxiu Li, Denzil Bernard, Nisar A. Amin, Peter Ouillette, Siân Jones, Kamlai Saiya-Cork, Brian Parkin, Kathryn Jacobi, Kerby Shedden, Shaomeng Wang, Alfred E. Chang, Mark S. Kaminski, Sami N. Malek

Blood (2015) 125 (4): 668–679.

https://doi.org/10.1182/blood-2014-06-582650

Published: 2015

Includes: Supplemental data

Journal Articles

Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples

Beatriz Herreros, Shaomeng Wang, Maria E. Rodriguez, Margarita Sanchez-Beato, Elena Domenech, Raul Cordoba, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Juan F. Garcia, José Francisco Tomás, Joaquín Martínez-López, Jose Luis Bello, Antonia Rodriguez, Raquel Villuendas, Miguel A. Piris

Blood (2010) 116 (21): 2470.

https://doi.org/10.1182/blood.V116.21.2470.2470

Published: 2010

Journal Articles

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

Jianting Long, Brian Parkin, Peter Ouillette, Dale Bixby, Kerby Shedden, Harry Erba, Shaomeng Wang, Sami N. Malek

Blood (2010) 116 (1): 71–80.

https://doi.org/10.1182/blood-2010-01-261628

Published: 2010

Includes: Supplemental data

Journal Articles

Molecular Heterogeneity as a Basis for Rational Therapeutics in Chronic Lymphocytic Leukemia.

Beatriz Herreros, Shaomeng Wang, James Robert Bischoff, PhD, Ruben Carro, Raul Córdoba, Julio Delgado, MD, PhD, Jose Antonio García-Marco, MD, PhD, Natalia Gómez, Juan F. García, José Francisco Tomáas, Joaquín Martínez-López, Antonia Rodríguez, Raquel Villuendas, Miguel A. Piris, MD

Blood (2009) 114 (22): 2348.

https://doi.org/10.1182/blood.V114.22.2348.2348

Published: 2009

Journal Articles

Enhanced Cytotoxicity in Chronic Myeloid Leukemia Primitive Progenitors by the Combined Action of Imatinib and An HDM2-Inhibitor

Luke F Peterson, PhD, Shaomeng Wang, Moshe Talpaz

Blood (2008) 112 (11): 3213.

https://doi.org/10.1182/blood.V112.11.3213.3213

Published: 2008

Journal Articles

Identification of p53 Aberration-Dependent as Well as Non-p53-Mediated Resistance to MDM2 Inhibitors in Acute Myelogenous Leukemia.

Jianting Long, MD, Peter Ouillette, Brian Parkin, Harry Erba, Shaomeng Wang, Sami Malek, MD

Blood (2008) 112 (11): 1607.

https://doi.org/10.1182/blood.V112.11.1607.1607

Published: 2008

Journal Articles

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia

Chris Saddler, Peter Ouillette, Lisa Kujawski, Sanjeev Shangary, Moshe Talpaz, Mark Kaminski, Harry Erba, Kerby Shedden, Shaomeng Wang, Sami N. Malek

Blood (2008) 111 (3): 1584–1593.

https://doi.org/10.1182/blood-2007-09-112698

Published: 2008

Includes: Supplemental data

Journal Articles

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.

Sami N. Malek, MD, Peter Ouillette, MT, ASCP, Lisa Kujawski, MD, Sanjeev Shangary, PhD, Moshe Talpaz, MD, Mark Kaminski, MD, Harry Erba, Kerby Shedden, PhD, Shaomeng Wang, PhD, Chris Saddler, BS

Blood (2007) 110 (11): 224.

https://doi.org/10.1182/blood.V110.11.224.224

Published: 2007

Journal Articles

Surface Plasmon Resonance Study of Apoptotic Regulators Bcl-2, Bcl-w, Bcl-XL, and Mcl-1 Indicate That the Preclinical Small Molecule Inhibitor (SMI) TW-37 Binds to the Hydrophobic Groove Competitively with tBid To Form a Heterodimer Which Cannot Be Disrupted by 200-Fold Molar Excess of TW-37.

Anton-Scott Goustin, PhD, Anshu Giri, B.S., Shaomeng Wang, Ph.D., Ayad Al-Katib, M.D., Mohammad M. Ramzi, Ph.D.

Blood (2007) 110 (11): 1606.

https://doi.org/10.1182/blood.V110.11.1606.1606

Published: 2007

Journal Articles

Evaluation of TW-37, a pan Bcl-2 Proteins Small-Molecule Inhibitor, Against Spectrum of Human B-Cell Lines and Patient-Derived Samples.

Ramzi M. Mohammad, PhD, Yuan Sun, MSc, Shaomeng Wang, PhD, Amro Aboukameel, MSc, Ayad M. Al-Katib, M.D.

Blood (2007) 110 (11): 4521.

https://doi.org/10.1182/blood.V110.11.4521.4521

Published: 2007

NARROW

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Probing Distinct Oncogene Addiction By Novel BCL-2 Inhibitors

Functional Analyses of BTK Mutations in Follicular Lymphoma

Functional Analyses of V-Atpase Mutations in Follicular Lymphoma

Analysis of 54 Follicular Lymphomas By Whole Exome Sequencing Identifies Multiple Novel Recurrently Mutated Pathways

BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice

Activating STAT6 mutations in follicular lymphoma

Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

Molecular Heterogeneity as a Basis for Rational Therapeutics in Chronic Lymphocytic Leukemia.

Enhanced Cytotoxicity in Chronic Myeloid Leukemia Primitive Progenitors by the Combined Action of Imatinib and An HDM2-Inhibitor

Identification of p53 Aberration-Dependent as Well as Non-p53-Mediated Resistance to MDM2 Inhibitors in Acute Myelogenous Leukemia.

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.

Surface Plasmon Resonance Study of Apoptotic Regulators Bcl-2, Bcl-w, Bcl-XL, and Mcl-1 Indicate That the Preclinical Small Molecule Inhibitor (SMI) TW-37 Binds to the Hydrophobic Groove Competitively with tBid To Form a Heterodimer Which Cannot Be Disrupted by 200-Fold Molar Excess of TW-37.

Evaluation of TW-37, a pan Bcl-2 Proteins Small-Molecule Inhibitor, Against Spectrum of Human B-Cell Lines and Patient-Derived Samples.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only